REG - Dechra Pharmaceutcls - Director/PDMR Shareholding

Dechra PharmaceuticalsAnnouncement

15/01/2024 17:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240115:nRSO7504Za&default-theme=true

RNS Number : 7504Z  Dechra Pharmaceuticals PLC  15 January 2024

 

 

15 January 2024

 

Dechra(®) Pharmaceuticals PLC

(Dechra or the Company)

 

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

 

 

Dechra Pharmaceuticals PLC announces that following the Court sanctioning the
Scheme at the Sanction Hearing on 12 January 2024, the following PDMRs
acquired ordinary shares of 1p each in the Company pursuant to awards granted
to them under the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the
LTIP), the Deferred Bonus Plan 2021 and the Global Save As You Earn Plan 2018
(SAYE) as detailed in the tables below. All shares were subject to the Cash
Offer of the Company at £38.75 per share:

 

Long Term Incentive Plan, SAYE and Deferred Bonus Plan

 

 Name           Capacity  Date of Grant       Award                Cost     Shares Acquired & Sold
 Ian Page       Director  22 September 2020*  Qualifying LTIP*     Nil      5,372
 Ian Page       Director  22 September 2020*  Qualifying CSOPŦ     £32.37   155
 Ian Page       Director  16 September 2021   LTIP**               Nil      18,551
 Ian Page       Director  9 September 2022    LTIP **              Nil      20,193
 Ian Page       Director  20 September 2022   Deferred Bonus Plan  Nil      3,580
 Ian Page       Director  19 October 2020     SAYE                 £28.68   627
 Paul Sandland  Director  22 September 2020*  LTIP*                Nil      2,335
 Paul Sandland  Director  16 September 2021   LTIP**               Nil      8,600
 Paul Sandland  Director  9 September 2022    Qualifying LTIP**    Nil      9,983

 Paul Sandland  Director  9 September 2022    Qualifying CSOP ±    £31.99   227
 Paul Sandland  Director  20 September 2022   Deferred Bonus Plan  Nil      2,293
 Paul Sandland  Director  19 October 2020     SAYE                 £28.68   627

 

*The vesting of the awards was subject to the achievement of performance
conditions which were satisfied to the extent that the awards vested at 16.4%.

Ŧ Ian Page exercised the linked tax qualifying option at an exercise price of
£32.37 as part of his LTIP award. 25 nil cost options were forfeited to the
value of that gain.

 ** Both the EPS and ROCE performance conditions for LTIP awards granted in
2021 and 2022 were deemed to have been met as detailed in the Co-Operation
Agreement between the Company and Freya Bidco Limited. The TSR performance
conditions was measured for both awards. The awards taking into account all of
the performance conditions vested at 90.8% for the 2021 grant and 100% for the
2022 grant. Both awards were pro rata for time.

± Paul Sandland exercised the linked tax qualifying option at an exercise
price of £31.99 as part of his LTIP award. 39 nil cost options were forfeited
to the value of that gain.

 

Deferred Bonus Plan 2021 (Cash Settled)

 

Ian Page and Paul Sandland were granted on 18 October 2023, 1,080 and 715
awards respectively under the Deferred Bonus Plan 2021. These were cash
settled in accordance with the Co-Operation Agreement between the Company and
Freya Bidco Limited.

 

 

 

 

The Notification of Dealing Forms set out below are provided in accordance
with the requirements of the UK Market Abuse Regulation.

 

Notification of Dealing Forms

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Ian Page

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 c)  Price(s) and volumes(s)                  Price(s)                               Volume(s)

                                              £Nil Cost                              5,372
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               N/A

     -    Total
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Ian Page

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 c)  Price(s) and volumes(s)                  Price(s)                               Volume(s)

                                              £32.37                                 155
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               155

     -    Total                               £32.37

                                              £5,017.35
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Ian Page

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 c)  Price(s) and volumes(s)                  Price(s)                               Volume(s)

                                              £Nil Cost                              18,551
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               N/A

     -    Total
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Ian Page

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 c)  Price(s) and volumes(s)                  Price(s)                               Volume(s)

                                              £Nil Cost                              20,193
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               N/A

     -    Total
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Ian Page

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Deferred Bonus Plan

 c)  Price(s) and volumes(s)                  Price(s)                            Volume(s)

                                              £Nil Cost                           3,580
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               N/A

     -    Total
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Ian Page

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Global Save As You Earn Plan

 c)  Price(s) and volumes(s)                  Price(s)                                 Volume(s)

                                              £28.68                                   627
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               627

     -    Total                               £28.68

                                              £17,982.36
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Paul Sandland

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 c)  Price(s) and volumes(s)                  Price(s)                               Volume(s)

                                              £Nil Cost                              2,335
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               N/A

     -    Total
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Paul Sandland

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 c)  Price(s) and volumes(s)                  Price(s)                               Volume(s)

                                              £Nil Cost                              8,600
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               N/A

     -    Total
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Paul Sandland

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 c)  Price(s) and volumes(s)                  Price(s)                               Volume(s)

                                              £Nil Cost                              9,983
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               N/A

     -    Total
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Paul Sandland

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 c)  Price(s) and volumes(s)                  Price(s)                               Volume(s)

                                              £31.99                                 227
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               227

     -    Total                               £31.99

                                              £7,261.73
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Paul Sandland

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Deferred Bonus Plan

 c)  Price(s) and volumes(s)                  Price(s)                            Volume(s)

                                              £Nil Cost                           2,293
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               N/A

     -    Total
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Paul Sandland

 2.  Reason for the notification
 a)  Position/status                          Director/PDMR

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Dechra Pharmaceuticals PLC
 b)  LEI code                                 213800J4UVB5OWG8VX82

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1 pence each

     Identification code

                                              ISIN: GB0009633180
 b)  Nature of the transaction                Acquisition of shares pursuant to the Company's Global Save As You Earn Plan

 c)  Price(s) and volumes(s)                  Price(s)                                 Volume(s)

                                              £28.68                                   627
 d)  Aggregated information

     -    Aggregate volume

     -    Price                               627

     -    Total                               £28.68

                                              £17,982.36
 e)  Date of the transaction                  2024.01.15
 f)  Place of the transaction                 Outside a trading venue

 

For further information, please contact:

 

Melanie Hall, Company
Secretary

Telephone number: 01606 814730

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products
business.  Our expertise is in the development, manufacture, and sales and
marketing of high quality products exclusively for veterinarians worldwide.
Dechra's business is unique as the majority of its products are used to treat
medical conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.  For more information
please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBLGDBUSBDGSU